Tag Archives: Trans Pacific Partnership

TPP and IP: The Economic Benefits of a Pacific Trade Agreement

scientists115x76

Ndp Analytics recently published a study on the economic benefits of intellectual property rights (IP) in the Trans-Pacific Partnership. They find that 2/3’s of the “economic benefits for the U.S. economy and the 11 partner countries would come from IP-intensive manufacturing industries.” They conclude that “the stronger the protection of IP rights under the TPP, the greater the value of trade leading to greater economic growth, additional jobs created, higher incomes, and development across countries.” Here Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

TPP and Innovation in the Bioeconomy: The Need for 12 Years of Data Protection

BIO Logo Horizontal 4C copy

A few weeks ago, BIO submitted a letter and white paper (PDF) to the U.S. Trade Representative outlining recommendations for policies to pursue with TPP negotiating partners to ensure intellectual property protection for innovative biologic products. Standards that enable biotechnology companies to protect and leverage their intellectual property are of critical importance to companies seeking breakthrough treatments and cures for patients in need worldwide. Implementing standards of protection that effectively protect innovation for biological products within the TPP region Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

Bi-partisan Senate Letter asking for 12 years of Data Protection in TPP

u.s. capitol

Senators Hatch and Kerry, along with 35 other Senators, sent a letter to Ambassador Kirk asking for 12 years of regulatory data protection consistent with U.S. law in the Trans Pacific Partnership Agreement. We are united in urging you to propose a strong minimum term of regulatory data protection for biologics consistent with U.S. law. As you are aware, U.S. law provides for a 12-year term of regulatory data protection for biologics and we believe that should serve Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Data Protection, Trans Pacific Partnership, and the US-Jordan FTA (Post 2 of 2)

Meeting

This post is a continuation of a previous post: Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2). 4.  Oxfam criticizes pharmaceutical innovators for not making all of their innovative drugs available in Jordan. Ryan responds: a.  Innovator companies introduced few new drugs before IP reform because local companies were using their know-how and clinical data to get marketing approval and brochures describing the drug’s therapeutic function and side effects Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2)

Meeting

The Trans Pacific Partnership (TPP) negotiation does not yet include a section on data protection (typically included in the Pharmaceutical Chapter of Free Trade Agreements).  Organizations against the inclusion of data protection in the TPP cite as evidence an Oxfam International study titled “All Costs, No Benefits: How TRIPS-plus intellectual property rules in the US-Jordan FTA affect access to medicines.” The Oxfam paper concludes that “medicine prices have increased drastically, and TRIPS-plus rules were partly Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,